The use of ECT in the treatment of schizophrenia
Abstract
ECT has been replaced by neuroleptics for the treatment of schizophrenia. The production of serious drug-related side effects, particularly tardive dyskinesia, raises the question of the efficacy and toxicity of ECT versus neuroleptics. Most of the studies in the English literature on the use of ECT in the treatment of schizophrenia are unacceptable according to contemporary criteria: the question of ECT versus neuroleptic drugs thus remains unanswered. In the few acceptable published studies, clinical response to ECT was inversely proportional to duration of schizophrenic symptoms. Schizophrenic patients with affective and catatonic symptoms responded best: those with chronic symptoms rarely responded. ECT does not alter the fundamental psychopathology of schizophrenia.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
